48th week of 2010 patent applcation highlights part 40 |
Patent application number | Title | Published |
20100303698 | PROCESS FOR REGENERATOR MIXING - A process is provided for increasing mixing in a regenerator. Streamlines of gas and some catalyst may form in a regenerator as a result of cyclone inlet horns positioned in the same direction. Overall mixing in the regenerator may decrease because of these streamlines. A dampening device may be used to interrupt the streamlines and increase mixing in the regenerator. The dampening device may be a baffle and direct streamlines from the outside of the chamber toward the center to collide and mix. In another embodiment, a dampening device may be a secondary disengager such as a T-disengager or an inverted can arrangement that may discharge gas and catalyst near the center of the upper chamber and interrupt the streamlines. In another embodiment, a dampening device may have swirl arms that redirect stream lines counter to the direction of flow. | 2010-12-02 |
20100303699 | METHOD OF REMOVING N20 FROM WASTE GAS - The invention provides a N | 2010-12-02 |
20100303700 | PROCESS FOR TREATING A GAS STREAM OR EFFLUENT - One exemplary embodiment can be a process for treating a tail gas stream from a sulfur recovery zone. Generally, the process includes passing the tail gas stream through, in sequence, a hydrogenation zone, a quench zone, and an acid gas removal zone using a solvent. The solvent can include at least one of a dimethyl ether of polyethylene glycol, a N-methyl pyrrolidone, a N-formyl morpholine, a N-acetyl morpholine, a tetrahydro-1,4-oxazine, and a mixture comprising diisopropanolamine and tetrahydrothiophene-1,1-dioxide. | 2010-12-02 |
20100303701 | Method For Making Electrode Active Materials - The present invention is directed to a method for making electrode active materials represented by the general formula: | 2010-12-02 |
20100303702 | METHOD OF PRODUCING POWDER, POWDER, AND ADSORPTION APPARATUS - A method of producing powder by using a first liquid and a second liquid to be mixed with the first liquid, the first liquid containing a first raw material and the second liquid containing a second raw material. The method comprises: mixing the first liquid and the second liquid to obtain a mixture; stirring the mixture for reacting the first raw material and the second raw material to thereby obtain a synthetic material and a slurry containing aggregates of the synthetic material; and drying the slurry to obtain powder of the synthetic material. In the mixing the first liquid and the second liquid, particle strength of the powder is adjusted by setting an initial temperature of mixing the first liquid with the second liquid. | 2010-12-02 |
20100303703 | Process for Producing Ammonia Synthesis Gas - The present invention concerns a process for producing ammonia synthesis gas from the reforming of hydrocarbons with steam in a primary reformer ( | 2010-12-02 |
20100303704 | METHOD FOR GROWING GROUP III-NITRIDE CRYSTALS IN A MIXTURE OF SUPERCRITICAL AMMONIA AND NITROGEN, AND GROUP III-NITRIDE CRYSTALS GROWN THEREBY - A method of growing group III-nitride crystals in a mixture of supercritical ammonia and nitrogen, and the group-III crystals grown by this method. The group III-nitride crystal is grown in a reaction vessel in supercritical ammonia using a source material or nutrient that is polycrystalline group III-nitride, amorphous group III-nitride, group-III metal or a mixture of the above, and a seed crystal that is a group-III nitride single crystal. In order to grow high-quality group III-nitride crystals, the crystallization temperature is set at 550° C. or higher. Theoretical calculations show that dissociation of NH | 2010-12-02 |
20100303705 | METHOD OF USING VOLATILE ORGANOMETALLICS AS BIOMASS GASIFICATION CATALYSTS - The present invention relates to a method for improving biomass gasification. By the present invention, volatile organometallics are contacted with a biomass before or during gasification. By this method, the biomass improves gas yields while reducing solid (tar) and liquid yields. In addition, the volatile organometallics interact with lignin in the biomass to produce methanol, which, in turn, results in a stable liquid or oil by-product or otherwise stabilizes the gasification process of the biomass. The presently disclosed method can also lead to increased syngas production and is potentially CO | 2010-12-02 |
20100303706 | PROCESS FOR THE PREPARATION OF GRAPHENE - The present invention relates to a process for the preparation of graphene which can be used in the development of graphene paper or films, graphene-based composites and articles for nanoelectronics, nanocomposites, batteries, supercapacitors, hydrogen storage and bioapplications. This process comprises reducing purified exfoliated graphite oxide in the presence of a base. | 2010-12-02 |
20100303707 | METHOD FOR PRODUCTION OF CALCIUM COMPOUNDS - The present invention relates to a method for production of calcium compounds having very low content of phosphorus and boron from an impure calcium chloride, solution containing phosphorus and boron, which method comprises the following steps: a) addition of a FeCl3-solution to the calcium chloride solution, b) adjusting the pH of the solution by addition of a base to between 3 and 9.5 for precipitation of iron hydroxide, iron phosphate and boron compounds, c) removal of the solid precipitate from the solution in step b) obtaining a purified calcium chloride solution, d) precipitation of a calcium compound from the solution from step c), and e) separation of the calcium compound from the solution in step d). | 2010-12-02 |
20100303708 | INORGANIC IODIDE, PRODUCTION METHOD THEREOF, AND PRODUCTION SYSTEM THEREOF - According to a method for producing an inorganic iodide in accordance with the present invention, it is possible to efficiently produce a highly pure inorganic iodide by reacting a hydrogen iodide gas with an inorganic base compound by bringing the hydrogen iodide gas into contact with the inorganic base compound. As such, it is possible to provide a simple and efficient method for producing an inorganic iodide. | 2010-12-02 |
20100303709 | Subterranean Well Production Saltwater Evaporation Station - A process comprising receiving production saltwater comprising water, salt, and hydrocarbons, separating substantially all of the hydrocarbons from the production saltwater, evaporating at least some of the water in the production saltwater to obtain the salt, and collecting the salt. Also disclosed is a facility comprising a settling pit, an evaporator in fluid communication with the settling pit and comprising a nozzle configured to emit a stream along a path, and a collection pit positioned under the path. | 2010-12-02 |
20100303710 | PROCESS FOR PRODUCING CHLORINE - Disclosed is a process for producing chlorine by oxidation of hydrogen chloride through a catalytic gas-phase reaction in the presence of a catalyst, wherein hydrogen chloride as a raw material is a by-product of synthesis of isocyanate by reacting phosgene and primary amine and oxidizing the hydrogen chloride through a catalytic gas phase reaction in the presence of a catalyst. The process is characterized by adjusting the sulfur content in carbon monoxide which is a raw material for the phosgene to 2000 vol. ppb or less. | 2010-12-02 |
20100303711 | Processes for Producing Synthetic Pyrite - Process of making high purity, synthetic FeS | 2010-12-02 |
20100303712 | HYDROGEN PRODUCTION CATALYST, PRODUCTION METHOD OF THE SAME AND HYDROGEN PRODUCTION METHOD - The drive of direct-heat-supply type reforming of hydrocarbon at ordinary temperature is necessary in order to realize a self-sustaining, on-site reforming type fuel cell system which does not necessitate the supply of energy from the outside. According to the invention, an oxide, CeO | 2010-12-02 |
20100303713 | Methanol Steam Reforming Catalysts - Novel catalysts, substantially free of Cu and Zn, useful for the reformation of methanol and steam into H | 2010-12-02 |
20100303714 | ONCOLYTIC VACCINIA VIRUS CANCER THERAPY - Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject administered at least 1×108 viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor. | 2010-12-02 |
20100303715 | Prostate-specific membrane antigen and uses thereof - This invention provides an isolated mammalian nucleic acid molecule encoding an alternatively spliced prostate-specific membrane (PSM′) antigen. | 2010-12-02 |
20100303716 | SWITCHABLE NANO-VEHICLE DELIVERY SYSTEMS, AND METHODS FOR MAKING AND USING THEM - The invention provides nanodevices or products of manufacture for use as drug delivery vehicles. In one aspect, the invention provides nanodevices or products of manufacture having on-off release mechanisms, e.g., that are “switchable”, or “actuatable” (for example magnetically or ultrasonically switchable), for compounds contained within, e.g., for use as drug delivery nano-vehicles having on-off drug release mechanisms, and their therapeutic applications. | 2010-12-02 |
20100303717 | Stabilized Uncoated Particles of Reversed Liquid Crystalline Phase Materials Cross Reference to Related Applications - Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound. | 2010-12-02 |
20100303718 | Stabilized Uncoated Particles of Reversed Liquid Crystalline Phase Materials - Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound. | 2010-12-02 |
20100303719 | ANTI-CANCER COMPOUNDS - The present invention relates to anti-cancer compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides analogs of the known anti-cancer compound amonafide, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with hyperproliferation. | 2010-12-02 |
20100303720 | VARIANTS OF HUMANIZED ANTI-CARCINOMA MAb CC49 - The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining | 2010-12-02 |
20100303721 | Use of Parasitic Biological Agents for Diseases Prevention and Control - The invention relates to a method of treating an excessive immune response including an aberrant/enhanced Th1 response by administering a helminthic parasite preparation in an amount sufficient to reduce the excessive immune response in an individual. This invention is generally directed to autoimmune diseases which involve an excessive immune response or an aberrant/enhanced Th1 response. More specifically, the present invention is directed to the treatment of Crohn's disease and ulcerative colitis, both known as IBD. While the present invention discloses specific information about the treatment of IBD, the disclosure is in no way limiting. Additionally, rheumatoid arthritis, type 1 diabetes mellitus, lupus erythematosis, sarcoidosis, multiple sclerosis, autoimmune thyroiditis, allergic rhinitis, colon polyps/colon cancer and asthma can be treated by the methods and compositions disclosed therein. | 2010-12-02 |
20100303722 | ARTICLES COMPRISING LARGE-SURFACE-AREA BIO-COMPATIBLE MATERIALS AND METHODS FOR MAKING AND USING THEM - The present invention provides articles of manufacture comprising biocompatible nanostructures comprising significantly increased surface area for, e.g., organ, tissue and/or cell growth, e.g., for bone, tooth, kidney or liver growth, and uses thereof, e.g., for in vitro testing of drugs, chemicals or toxins, or as in vivo implants, including their use in making and using artificial tissues and organs, and related, diagnostic, screening, research and development and therapeutic uses, e.g., as drug delivery devices. The present invention provides biocompatible nanostructures with significantly increased surface area, such as with nanotube and nanopore array on the surface of metallic, ceramic, or polymer materials for enhanced cell and bone growth, for in vitro and in vivo testing, cleansing reaction, implants and therapeutics. The present invention provides optically transparent or translucent cell-culturing substrates. The present invention provides biocompatible and cell-growth-enhancing culture substrates comprising elastically compliant protruding nanostructure substrates coated with Ti, TiO | 2010-12-02 |
20100303723 | DRUG DELIVERY SYSTEMS USING FC FRAGMENTS - The present invention provides drug delivery systems comprising FcRn binding partners (e.g., FcRn binding partner, Fc fragment) associated with a particle or an agent to be delivered. Inventive drug delivery systems allow for binding to the FcRn receptor and transcytosis into and/or through a cell or cell layer. Inventive systems are useful for delivering therapeutic agents across the endothelium of blood vessels or the epithelium of an organ. | 2010-12-02 |
20100303724 | Polypeptides, Cyclic Polypeptides and Pharmaceutical Comprising Thereof for Non Invasive Specific Imaging of Fibrosis - The present invention relates to diagnostic imaging and in particular to the diagnostic imaging of fibrosis. More particularly, the present invention provides a polypeptides, cyclic polypeptides and pharmaceutical compositions suitable for the non-invasive visualization of fibrosis. The polypeptide of the invention may comprise an amino acid sequence consisting of: X1-X2-M-H-G-L-X7-L-X9-X10-D-E wherein amino acid X1 is R, F or P; amino acid X2 is F or V; amino acid X7 is Q, H or L; amino acid X9 is W or G and amino acid X10 is A or D. | 2010-12-02 |
20100303725 | Technetium- and Rhenium-Bis(heteroaryl) Complexes, and Methods of Use Thereof - One aspect of the invention relates to complexes of a radionuclide with various heteroaryl ligands, e.g., imidazolyl and pyridyl ligands, and their use in radiopharmaceuticals for a variety of clinical diagnostic and therapeutic applications. Another aspect of the invention relates to imidazolyl and pyridyl ligands that form a portion of the aforementioned complexes. Methods for the preparation of the radionuclide complexes are also described. Another aspect of the invention relates to imidazolyl and pyridyl ligands based on derivatized lysine, alanine and bis-amino acids for conjugation to small peptides by solid phase synthetic methods. Additionally, the invention relates to methods for imaging regions of a mammal using the complexes of the invention. | 2010-12-02 |
20100303726 | HUMANIZED COLLAGEN ANTIBODIES AND RELATED METHODS - The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis. | 2010-12-02 |
20100303727 | OPTICAL IMAGING AGENTS - The present invention relates to imaging agents suitable for in vivo optical imaging, which comprise conjugates of pentamethine cyanine dyes having reduced non-specific binding, e.g. to plasma proteins. This is achieved by control of the nature and location of the sulfonic acid substituents, in particular the sulfoalkyl groups. Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods. | 2010-12-02 |
20100303728 | CASPASE IMAGING PROBES - The present invention relates to molecular probes of formula (I) | 2010-12-02 |
20100303729 | CYANOCHROME FLUOROPHORES - Genetically-engineered cyanochrome fluorophore molecules (fluorophores) with increased fluorescence and with absorbing fluorescence in the blue and green (blue/green) portion of the light spectrum are provided. These fluorophores are derived from the domains of phytochromes, and in particular cyanobacterial phytochromes. Methods for generating these fluorophores and various applications of these fluorophores are also provided. | 2010-12-02 |
20100303730 | Methods of making iron-containing nanoparticles - A method of making iron-containing nanoparticles (e.g., magnetite nanoparticles) that includes contacting an iron-containing precursor with a reducing agent at a temperature less than 200° C. and allowing the mixture to react to form magnetite nanoparticles. | 2010-12-02 |
20100303731 | Systems, devices, methods, and compositions including selectively accessible ferromagnetic structures - Magnetic resonance systems, devices, methods, and compositions are provided. A nuclear magnetic resonance imaging composition includes, but is not limited to, a plurality of ferromagnetic microstructures configured to generate a time-invariant magnetic field within at least a portion of one or more internal surface-defined voids. In an embodiment, a plurality of ferromagnetic microstructures includes one or more selectively accessible ferromagnetic microstructures. | 2010-12-02 |
20100303732 | DIAGNOSTIC SUBSTANCES FOR OPTICAL IMAGING TESTING ON THE BASIS OF NANOPARTICULAR FORMULATIONS - The present invention relates to the provision of nanoparticular formulations comprising a PEG-alkyl block copolymer and a near infrared fluorescent dye, the preparation of these nanoparticular formulations, pharmaceutical compositions comprising the nanoparticular formulations of the present invention, as well as their use as contrast medium. | 2010-12-02 |
20100303733 | Systems, devices, methods, and compositions including ferromagnetic structures - Magnetic resonance systems, devices, methods, and compositions are provided. A nuclear magnetic resonance imaging composition includes, but is not limited to, a plurality of ferromagnetic microstructures configured to generate a time-invariant magnetic field within at least a portion of one or more internal surface-defined voids. In an embodiment, at least one of the plurality of ferromagnetic microstructures includes one or more targeting moieties attached thereof. | 2010-12-02 |
20100303734 | CONTRAST AGENTS - The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing two linked iodinated phenyl groups of the general formula (I): R—CO—N(R)—X—N(R)—CO—R and salts or optical active isomers thereof, wherein one R denotes a hydrogen atom or a C | 2010-12-02 |
20100303735 | METHOD AND ARRANGEMENT FOR FORMING VARIABLE COLOR PHARMACEUTICAL PRODUCTS - Methods and arrangements for forming a color gradient on a pharmaceutical dosage forms such as tablets are disclosed. In preferred aspects of the invention, a coating layer is applied to a tablet core so that the coating layer is different from the color of the tablet core. The coating layer is etched by one or more lasers to remove selected portions thereof and reveal the core. Removal of selected portions of the coating layer, while other portions remain unetched by the laser(s), causes a variation in the color of the coating layer. The color of the tablet core may be visible at locations at which portions of the coating layer have been entirely removed while the color of the coating layer, i.e., the color of any of the color coatings thereof, is visible at locations at which portions of the coating layer have been only partially removed or not removed at all. | 2010-12-02 |
20100303736 | ANTI-IL-9 ANTIBODY FORMULATIONS AND USES THEREOF - The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to an IL-9 polypeptide, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to an IL-9 polypeptide, which formulations are substantially free of surfactants, sugars, sugar alcohols, amino acids other than histidine (preferably with pKa values of less than 5 and above 7), and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating a disease or disorder associated with or characterized by aberrant expression and/or activity of an IL-9 polypeptide, a disease or disorder associated with or characterized by aberrant expression and/or activity of the IL-9R or one or more subunits thereof, an autoimmune disease, an inflammatory disease, a proliferative disease, or an infection (preferably, a respiratory infection), or one or more symptoms thereof, utilizing the liquid formulations of the present invention. | 2010-12-02 |
20100303737 | Tooth-Cleaning Formulation - A tooth-cleaning formulation which contains Himalaya salt in an unadulterated and also non-heat-treated form and/or Sango coral, with the Himalaya salt being used as a direct natural raw material and not being heated and sterilized itself. | 2010-12-02 |
20100303738 | NON-CONTACT PRINTED COMESTIBLE PRODUCTS AND APPARATUS AND METHOD FOR PRODUCING SAME - The present disclosure provides an apparatus and method for packaging a non-contact printed edible substrate as well as the resultant packaged product. The packaging apparatus may include a non-contact printer, a carrier, and a package located at a discharge position. The carrier may be constructed and arranged to transport the edible substrate from the print position to the package and orient same in the package so that the printed ink indicia is visible through at least a portion of a panel of the package. At a print position, the non-contact printer is constructed and arranged to apply an edible ink indicia to an edible substrate. The packaging apparatus may form a packaged product having a plurality of compartments where at least one compartment at least partially defined by a panel. The interior of the compartment contains at least one edible substrate comprising a surface and a printed edible ink indicia on the surface so that the ink indicia is visible through at least a portion of the panel. | 2010-12-02 |
20100303739 | Highly Concentrated Fatty Alcohol Sulfate Preparation - Concentrated fatty alcohol sulfate preparations which comprise at least 35% by weight of fatty alcohol sulfate (FAS) are described. The compositions are aqueous, but, besides the FAS, also comprise polyols, fatty acid alkylamides and/or oil-soluble betaines. They are suitable for the production of detergents and cleaners, but also for the production of cosmetic compositions, in particular dental care compositions. | 2010-12-02 |
20100303740 | PROCESS FOR PRODUCING (3S)-I-MENTHYL 3-HYDROXYBUTYRATE AND SENSATE COMPOSITION - The present invention provides a cooling component or sensate component which does not have undesirable stimulus feeling, bitterness and the like and is excellent in the persistence of refresh-feeling and cool-feeling, a sensate composition which comprises the same, and various products that comprise said sensate composition. The present invention relates to a cooling agent comprising (3S)-1-menthyl 3-hydroxybutyrate represented by the following formula (I) | 2010-12-02 |
20100303741 | WOLFBERRIES AND INFLAMMATION - The present invention relates in general to the field of inflammation. In particular the present invention relates to the use of natural compounds for the preparation of a product to treat or prevent inflammation. For example an extract of wolfberry was shown to have anti-inflammatory properties. One embodiment of the present invention relates to the use of a primary composition comprising wolfberries or a part thereof for the preparation of a product to treat or prevent inflammation. | 2010-12-02 |
20100303742 | Skin compositions containing hydrocortisone - Skin compositions comprising, hydrocortisone; allantoin; and a water-based vehicle that is essentially free of petroleum jelly, mineral oil and wax; and related method for protecting, healing and/or soothing the skin comprising: applying an effective amount of a cosmetic preparation selected from the group consisting of hand cream, foot cream, body cream, lip cream, lip gloss, lip stick, gel, balm and lotion to the skin surface; wherein said cosmetic preparation includes a skin composition made of hydrocortisone; allantoin; and a water-based vehicle that is essentially free of petroleum jelly, mineral oil and wax; and said effective amount is enough to protect, heal and/or soothe the skin surface. | 2010-12-02 |
20100303743 | Personal Care Compositions Containing Hydrophobic Silicone-Organic Gel Blends - Personal care or healthcare compositions are disclosed comprising a hydrophobic silicone organic elastomer gel blend having viscosity of at least 50 Pa-s. The hydrophobic silicone organic elastomer gel blend contains a silicone organic elastomer and a carrier fluid. The gel blend may be prepared by shearing a silicone organic elastomer or silicone organic elastomer gel with the carrier fluid. | 2010-12-02 |
20100303744 | PERSONAL-CARE COMPOSITION COMPRISING OIL-SOLUBLE SOLID SUNSCREENS - In one embodiment, a personal-care composition in the form of a water-in-oil emulsion comprises at least about 10% of a non-polar silicone oil; from about 0.1% to about 10% of a first oil-soluble solid sunscreen; and from about 0.1% to about 10% of a second oil-soluble solid sunscreen. The weight ratio of the first sunscreen to the second sunscreen may be from about 0.8 to about 2.0, or from about 1.0 to about 1.5. The first sunscreen may be oxybenzone. The second sunscreen may be avobenzone. The composition may further comprise a skin-care active selected from the group consisting of a vitamin B | 2010-12-02 |
20100303745 | SKIN BRONZER - The invention provides a composition having a sunblock and tanning effect containing dihydroxyacetone and a broad spectrum UV blocker having a SPF of at least about 25. | 2010-12-02 |
20100303746 | GRINDING AIDES FOR MICRONIZED ORGANIC UV ABSORBERS - A method of preparing a composition, comprising (a) a micronised insoluble organic UV absorber, which method comprises grinding the insoluble organic UV absorber, in coarse particle form, in a grinding apparatus, in the presence of a grinding aid selected from the groups (b | 2010-12-02 |
20100303747 | SKIN TREATMENT COMPOSITIONS - Arbutin-containing compositions are useful for topical application to provide enhanced luminosity, brightening or lightening to the skin of a user and are at least 85% as efficacious (with regard to skin lightening, when used alone or in a system as measured by Chromameter® b* parameter values) as substantially corresponding compositions containing hydroquinone in an amount from about the same molar amount to about 1.5 times the molar amount of arbutin. | 2010-12-02 |
20100303748 | METHOD FOR LIGHTENING AND/OR COLORING HUMAN KERATIN FIBERS USING A COMPOSITION COMPRISING AN AMINOTRIALKOXY SILANE OR AMINOTRIALKENYLOXY SILANE COMPOUND AND DEVICE - The present disclosure provides a method of lightening and/or coloring human keratin fibers comprising applying to the keratin fibers * at least one first composition comprising at least one fat, at least one nonionic surfactant, at least one specific aminotrialkoxy silane or aminotrialkenyloxy silane compound, and applying * at least one second composition comprising at least one oxidizing agent. It also provides a multiple-compartment device in which at least one compartment comprises the above-mentioned at least one first composition and at least one other compartment comprises the at least one oxidizing composition. | 2010-12-02 |
20100303749 | Antiperspirant Active Compositions Having SEC Chromatogram Exhibiting High SEC Peak 4 Intensity - An antiperspirant active composition comprising an aluminum salt having an aluminum to chloride molar ratio of about 0.3:1 to about 3:1, exhibiting a SEC chromatogram having SEC Peak 4 to Peak 3 intensity ratio of at least 7 and a Peak 4 intensity greater than a Peak 5 intensity in aqueous solution. The composition can optionally include zirconium. Also, methods and processes or making the same. | 2010-12-02 |
20100303750 | POLYSILOXANE BLOCK COPOLYMERS - This invention encompasses novel amphiphilic block copolymers comprising polysiloxane blocks and polycationic blocks. The polycationic blocks are formed from diallyldialkylammonium derivatives. The formed block copolymers are particularly useful for treating or conditioning keratinous substances such as hair or skin. | 2010-12-02 |
20100303751 | TREATMENT COMPOSITION - A concentrated treatment composition includes a bird repelling composition, a glycol, and a fragrance-containing/odor control composition. The concentrated treatment composition provides a stable product that is miscible with water. Methods for applying to the treatment compositions are also provided. | 2010-12-02 |
20100303752 | USE OF POLYMERIC GUANIDINES FOR CONTROLLING MICROORGANISMS - The invention relates to the use of polymeric guanidinium hydroxides based on a diamine which contains oxyalkylene chains and/or alkylene groups between two amino groups, obtainable by polycondensation of a guanidine acid addition salt with the diamine, whereby a polycondensation product in the form of a salt is obtained, which subsequently is converted into the hydroxide form via basic anion exchange, for controlling microorganisms. | 2010-12-02 |
20100303753 | Oligomer Conjugates of Lidocaine and Its Derivatives - The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. | 2010-12-02 |
20100303754 | PROCESS FOR PREPARATION OF CYCLODEXTRIN OLIGOMERS OR POLYMERS, PRODUCTS OBTAINED AND USES - A process for the preparation of cyclodextrin oligomers or polymers, whereby the cyclodextrin molecules are coupled to one another covalently via a spacer arm, based on a coupling reaction between an alkyne and an azide producing the formation of an aromatic heterocyclic bridge between the coupled units. Also described are the cyclodextrin oligomers or polymers that are obtained and their uses. | 2010-12-02 |
20100303755 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2010-12-02 |
20100303756 | Methods of Treating Urogenital-Neurological Disorders Using Interleukin Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such TVEMPs and compositions. | 2010-12-02 |
20100303757 | Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating chronic neurogenic inflammation in a mammal using such TVEMPs and compositions. | 2010-12-02 |
20100303758 | Novel Glucocorticoid Receptor Agonists - This invention relates to novel glucocorticoid receptor agonists of formula (I): | 2010-12-02 |
20100303759 | RECOMBINANT HUMAN INTERFERON-LIKE PROTEINS - This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer. | 2010-12-02 |
20100303760 | TREATMENT AND/OR PREVENTION OF CANCER AND/OR ARTHRITIS - The invention relates to the use of INSP163 for treatment and/or prevention of cancer and/or musculoskeletal/connective tissue disorder, in particular of lung cancer and/or osteoarthritis. Combinations of INSP163 with an interferon, a TNF antagonist or a further anti-cancer or anti-arthritis agent are also within the present invention. | 2010-12-02 |
20100303761 | Lipidized Interferon and Uses Thereof - The present invention is directed to methods and compositions useful in increasing in mammals the absorption and retention of polypeptides. The invention provides lipid-conjugated interferon having increased liver uptake and increased plasma half-life. | 2010-12-02 |
20100303762 | Antifungal Polypeptides - Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include novel amino acid sequences, and variants and fragments thereof, for antipathogenic polypeptides that were isolated from microbial fermentation broths. Nucleic acid molecules comprising nucleotide sequences that encode the antipathogenic polypeptides of the invention are also provided. A method for inducing pathogen resistance in a plant using the nucleotide sequences disclosed herein is further provided. The method comprises introducing into a plant an expression cassette comprising a promoter operably linked to a nucleotide sequence that encodes an antipathogenic polypeptide of the invention. Compositions comprising an antipathogenic polypeptide or a transformed microorganism comprising a nucleic acid of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Transformed plants, plant cells, seeds, and microorganisms comprising a nucleotide sequence that encodes an antipathogenic polypeptide of the invention, or variant or fragment thereof, are also disclosed. | 2010-12-02 |
20100303763 | METHOD FOR DECREASING ABDOMINAL GIRTH BY ADMINISTERING A BIFIDOBACTERIUM BACTERIA - A method for decreasing abdominal girth in a subject by administering a probiotic, preferably a bacteria of the | 2010-12-02 |
20100303764 | Sweet Whey Based Biopesticide Composition - A biopesticide composition for pest management that includes a sweet whey product and spores mixed with a carrier to form a growing environment in a target region. The growing environment forms a micro-factory that is suitable for spore growth, such that the number of spores substantially increases from a first spore concentration prior to application to the target region to a second spore concentration after a period of time. The biopesticide composition may include other additives that modify the micro-factory in a manner that facilitates spore growth and/or increases the probability that a target pest, e.g., an insect, will come into contact with the spores. | 2010-12-02 |
20100303765 | Scaffoldless Constructs for Tissue Engineering of Articular Cartilage - A process for culturing chondrocytes to form constructs which contain higher percentages of cells that retain the chondrocytic phenotype are disclosed. The tissue engineered constructs may be formed into neocartilage-containing compositions for a variety of in vitro and in vivo purposes. Methods of treating individuals in need of articular cartilage growth by implanting a new composition are disclosed. | 2010-12-02 |
20100303766 | CELL POPULATION WITH ENHANCED TRANSPLANTATION ACTIVITY - A cell having excellent migration ability and engraftment ability to tissues is required for the restoration and the like of damaged tissues making use of a hematopoietic stem cell transplantation or a stem cell transplantation. By the present invention, a cell population having excellent migration ability and engraftment ability to tissues, a pharmaceutical preparation comprising said cell and a transplantation method of said cell are provided. The cell of the present invention is useful for hematopoietic stem cell transplantation and restoration of damaged tissues using stem cell transplantation and the like. | 2010-12-02 |
20100303767 | METHODS FOR COMPACT AGGREGATION OF DERMAL CELLS - The invention provides for a method for aggregating dermal papilla cells or dermal sheath cells or a combination thereof, the method comprising: growing dermal papilla cells or dermal sheath cells or a combination thereof in suspension culture; and contacting the culture with an effective amount of an enzyme, wherein a substrate of the enzyme is an extracellular matrix molecule in the suspension culture, so as to aggregate dermal papilla cells or dermal sheath cells. The culture may be a hanging drop culture and the enzyme may be a hyaluronidase. | 2010-12-02 |
20100303768 | Isolated lineage negative hematopoietic stem cells and methods of treatment therewith - Isolated, mammalian, adult bone marrow-derived, lineage negative hematopoietic stem cell populations (Lin | 2010-12-02 |
20100303769 | Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease - Acute and chronic heart disease is treated using a rational, multi-tier approach. A patient is pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells. The progress of treatment is continuously monitored by echo-cardiogram with growth factor treatment and/or stem cell administration adjusted according to the results of the echo-cardiogram or clinical status of the patient. Heart disease is also treated by a method that comprises administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy. | 2010-12-02 |
20100303770 | METHODS FOR CULTURING DERMAL CELLS FOR TREATMENT OF SKIN INJURIES SUCH AS BURNS - The present invention relates to novel methods of growing or otherwise producing unpassaged or minimally-passaged dermal cells from a small biopsy specimen for treating skin injuries significantly larger than the biopsy. | 2010-12-02 |
20100303771 | GABA NEURON PROGENITOR CELL MARKER 65B13 - The present inventors identified a selective marker 65B13 for GABA neuron progenitor cells of the spinal dorsal horn and cerebellum, and successfully isolated GABA neuron progenitor cells using antibodies that bind to a protein encoded by the gene. 65B13 was demonstrated to be useful as a marker to isolate GABA-producing neuron progenitor cells in the spinal dorsal horn and cerebellum. GABA neuron progenitor cells can be efficiently identified or isolated by using the identified marker as an indicator. | 2010-12-02 |
20100303772 | METHOD AND SYSTEM FOR DIRECTING A LOCALIZED BIOLOGICAL RESPONSE TO AN IMPLANT - The invention provides methods for directing a localized biological response of a mammalian body to an implant disposed within the body. In one embodiment, a delivery system is positioned outside the body and adjacent to the implant within the body. The delivery system comprises a first tissue response modifier effective for directing a localized biological response of the body to the implant. The tissue response modifier is nonsurgically delivered from the delivery system into the body in a quantity effective to direct the localized biological response of the body to the implant. The invention also provides an implant system for long-term use comprising an implant and nonsurgical means for delivering a tissue response modifier through the epidermis of the body, the tissue response modifier effective for directing a localized biological response of the body to the implant. | 2010-12-02 |
20100303773 | TSP-1, TSP-2, IL-17BR AND HB-EGF ASSOCIATED WITH STEM CELL ACTIVITY AND USE THEREOF - Thrombospondin 1 (TSP-1), TSP-2, interleukin 17B receptor (IL-17BR) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) associated with stem cell activity and use thereof. | 2010-12-02 |
20100303774 | METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS - Regenerative cells present in adipose tissue are used to treat patients, including patients with musculoskeletal diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, regenerative cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic musculoskeletal benefit. | 2010-12-02 |
20100303775 | Generation of Genetically Corrected Disease-free Induced Pluripotent Stem Cells - Methods and compositions for the generation and use of genetically corrected induced pluripotent stem cells are provided. | 2010-12-02 |
20100303776 | Methods and compositions for regulated expression of multiple nucleic acids - The present invention provides a cell comprising a first heterologous nucleic acid construct and a second heterologous nucleic acid construct, wherein each of said first and second heterologous nucleic acid constructs comprises: A. a first nucleotide sequence encoding a nucleotide sequence of interest (NOI); and B. a second intronic nucleotide sequence comprising: i) a first set of splice elements defining a first intron that is removed by splicing to produce a first RNA molecule encoded by said first nucleotide sequence in the absence of activity at a second set of splice elements; and ii) the second set of splice elements defining a second intron different from said first intron, wherein said second intron is removed by splicing to produce no RNA molecule and/or to produce a second RNA molecule that is not encoded by said first nucleotide sequence, wherein each said first nucleotide sequence of each of said first and second heterologous nucleic acid constructs is different from one another and wherein each said second intronic nucleotide sequence of each of said first and second heterologous nucleic acid constructs is different from one another. | 2010-12-02 |
20100303777 | DELIVERY OF BINDING MOLECULES TO INDUCE IMMUNOMODULATION - Delivery of binding molecules, such as antibodies, antibody fragments, single antibody variable domains, soluble receptors, ligands and dominant negative variants, to induce an immunomodulation in a patient is disclosed. More specifically, a medicament which includes micro-organisms which produce the binding molecules is described for the treatment of immune mediated diseases. | 2010-12-02 |
20100303778 | COMPOSITION FOR HUMAN AND/OR ANIMAL NUTRITION, USES THEREOF AND YEASTS - The invention relates to novel yeast strains, to the yeasts resulting from these strains, to a composition containing at least one | 2010-12-02 |
20100303779 | Non-Conventional NKT Cells for Use in Cancer Therapy - The invention relates to the use of CD Id-independent NKT cells, for the preparation of a pharmaceutical composition for treating a tumor in a patient. Said CD1d-independent NKT cells may be obtained by (a) culturing a population of T cells under conditions which suppress TGFβ signalling pathway, and (b) selecting the cells which exhibit at least one NK marker. | 2010-12-02 |
20100303780 | COMPOSITIONS FOR TREATING AN INTESTINAL INFLAMMATORY CONDITION - Compositions comprising human Tr1 cells directed to a food antigen from common human diet and methods for treating an intestinal inflammatory condition. | 2010-12-02 |
20100303781 | Treatment - The invention provides use of an IdeS polypeptide, or a polynucleotide encoding an IdeS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies. | 2010-12-02 |
20100303782 | PROBIOTIC COMPOSITION USEFUL FOR DIETARY AUGMENTATION AND/OR COMBATING DISEASE STATES AND ADVERSE PHYSIOLOGICAL CONDITIONS - A probiotic composition including the bacilli (1) | 2010-12-02 |
20100303783 | Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such TVEMPs and compositions. | 2010-12-02 |
20100303784 | PREPARATION FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISORDERS - The present invention relates to a preparation suitable for the prevention and/or treatment of vascular disorders, comprising the following fractions:
| 2010-12-02 |
20100303785 | NOVEL THERAPEUTICS BASED ON TAU/MICROTUBULE DYNAMICS - The invention is based on the discovery of a novel neuroprotective peptide. In addition, the invention rests on the discovery that the NAP peptide enhances the association of tau and the brain-specific beta tubulin subunit. In addition, NAP modifies microtubule assembly and dynamics, in part, by affecting the tyrosination of microtubule proteins. The invention provides compositions and methods for treatment and prevention of neuronal disorders, including NAP-binding and tau-binding agents, tau peptide mimetics, NAP-like and NAP-like tau peptide mimetics. | 2010-12-02 |
20100303786 | Stabilisation of Liquid-Formulated Factor VII(A) Polypeptides by Aldehyde-Containing Compounds - The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilising agent (iii) comprising a R—CHO motif, e.g. Benzaldehyde, 3-hydroxybenzaldehyde, 4-hydroxybenzaldehyde, or 5-formyl-4-methylimidazole. | 2010-12-02 |
20100303787 | Methods of Treating Urogenital-Neurological Disorders Using Galanin Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such TVEMPs and compositions. | 2010-12-02 |
20100303788 | Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating chronic neurogenic inflammation in a mammal using such TVEMPs and compositions. | 2010-12-02 |
20100303789 | Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating chronic neurogenic inflammation in a mammal using such TVEMPs and compositions. | 2010-12-02 |
20100303790 | USE OF BILIVERDIN REDUCTASE (BVR) AND BVR PEPTIDE FRAGMENTS TO TREAT CORONARY DISORDERS - The present invention relates to methods and compositions for treating coronary disorders and preventing cardiac cell death that involve the use of biliverdin reductase (“BVR”) or BVR peptides to stabilize the expression and activity of intracellular HO-2 in cardiac cells. The present invention also relates to methods and compositions for inducing cancer cell death in a patient having cancer that involve the use of inhibitory BVR peptides to destabilize intracellular HO-2 expression and activity, thereby augmenting cell death. | 2010-12-02 |
20100303791 | Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating chronic neurogenic inflammation in a mammal using such TVEMPs and compositions. | 2010-12-02 |
20100303792 | PROTEIN SYNTHESIS REQUIRED FOR LONG-TERM MEMORY IS INDUCED BY PKC ACTIVATION ON DAYS PRECEDING ASSOCIATIVE LEARNING - The present invention provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC. | 2010-12-02 |
20100303793 | COMBINATION THERAPY FOR CARDIAC REVASCULARIZATION AND CARDIAC REPAIR - An agonist of the non-proteolytically activated thrombin receptor and an angiogenic growth factor can be used in combination in methods of therapy to stimulate cardiac revascularization, to stimulate vascular endothelial cell proliferation, to stimulate vascular endothelial cell migration and to promote repair of cardiac tissue. | 2010-12-02 |
20100303794 | Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such TVEMPs and compositions. | 2010-12-02 |
20100303795 | MARKER OF PROSTATE CANCER - An SLC18A2 gene serves as a marker of prostate cancer. Methods are provided for diagnosing prostate cancer, predicting or prognosticating the disease outcome, predicting recurrence following surgery, and monitoring disease progression in an individual having prostate cancer. The methods relate to determining the methylation state of an SLC18A2 gene and/or determining the level of transcription or translation of the gene in a sample from the individual. Methods of treating prostate cancer are also provided. The invention also pertains to compositions and kits for use in the methods. | 2010-12-02 |
20100303796 | Method for Treating Systemic DNA Mutation Disease - A treatment for systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA and, more particularly, to a treatment of diabetes mellitus and atherosclerosis. The inventive method consist from introducing a treatment agent into a circulating blood system of a patient diagnosed with systemic DNA mutation diseases when said treatment agent destroys extracellular DNA in said blood of said patient and wherein said treatment agent used to destroy said extracellular DNA is a DNASE enzyme: said agent might be administered in doses and regimens which sufficient to decrease number average molecular weight of circulating extracellular blood DNA in the blood of said patient; | 2010-12-02 |
20100303797 | Use of p97 As An Enzyme Delivery System For The Delivery of Therapeutic Lysosomal Enzymes - The present invention provides for compositions and methods for treating, ameliorating or preventing a lysosomal storage disease by administering to a patient suffering from a lysosomal storage disease a P97 conjugated with an enzyme which is capable of transportation into the lysosomes of cells on either sides of the blood brain barrier. | 2010-12-02 |